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shunt < 2mm) of the ASD in 95.8% of 48 patients in whom the ASO was implanted and 
96.1% of 26 surgical patients. Although surgical ASD closure was performed in younger 
patients (p<0.005) with slightly larger defects (p=0.02), there was no significant differ- 
ence between the 2 groups in average Qp/Qs ratio (p=0.3). There were no deaths in 
either group. Complications occurred in 10.4% of patients in whom the ASO was 
implanted, all of which were minor, and 42.3% of patients who underwent surgery, 2 of 
which were major. The mean estimated cost (in FY2000 U.S. dollars) per case treated 
with the ASO was $11,541 (+/- $2,380), as compared with $22,695 (+/- $6,250) per case 
treated surgically (p<0.005). The average length of hospital stay per case treated with 
the ASO was 1,0 day (+/-0.2), as compared with 6.2 days (+/-3.0) per case treated surgi- 
cally (p<0.005). Sensitivity analyses based on our data identified no plausible situations 
in which the costs of surgery and of implantation of the ASO would be equal. 
Conclusions: The equally effective and less costly Amplatzer septal occluder appears 
superior to surgical closure of isolated secundum atrial septal defects in qualifying 
patients. The transcatheter method is also associated with significantly less morbidity. 
Consequently, our results support the use of the Amplatzer septal occluder as an alterna- 
tive to surgery for the management of this common congenital lesion. 
1048-169 Are Minimal Elevations of Postoperative Cardiac 
Troponin I Levels Following General Surgery 
Prognoetically Important? 
Michael J. Porter, John F. Moran, David Leder, Stephan Kahn, Krystyna Malinowska, 
Loyola University Health System, Maywood, Illinois. 
Introduction: Cardiac troponin I has a high specificity for cardiac injury, because cardiac- 
specific antibodies do not cross-react with skeletal muscle isoforms of troponin I. Cardiac 
treponin I elevations >0.1 ng/ml have important prognostic value in patients with acute 
coronary syndrome. However, the significance of troponin I levels between 0.1 and 2.5 
ng/ml in patients following general surgery is unclear. 
Methods: We retrospectively reviewed medical records of 304 patients who had under- 
gone abdominal, orthopedic, and other general surgical procedures in our institution 
between 7/99 and 6/00. Patients with clinical evidence of acute coronary syndrome or 
myocardial infarction were excluded from the study. We identified 167 patients with a 
measurable post-operative (OP) peak troponin level between 0.1 and 2.5 ng/ml. The car- 
diac troponin I levels were obtained with a chemiluminescent echnique on the Bayer 
ACS Centaur immunoassay analyzer (Bayer Corp., East Walpole, MA). Troponin I levels 
suggested a non-linear tendency, so log transform of troponin I levels was used to ana- 
lyze data by Pearson's correlation, the Student-t test, and ANOVA. 
Results: Out of 167 patients, 48% were men and 52% were women with mean age of 
72.9-J:13.1 (range 26 to 99) years, 33.5% were on ~-blockers, and 70.1% had abnormal 
post-OP electrocardiograms, with a mean follow-up of 303.5+~39.3 (range 0 to 737) 
days. There were significantly more complications at one month, two months and three 
months post-OP with more elevated troponin I levels t=21.2, p<0.001; t=22.0, p<0.001 
and t=18.5, p<0.001, respectively. Complications during the first three post-OP months 
included 4 acute myocardial infarctions, 8 cases of congestive heart failure, and 19 
deaths. Most of the troponin I elevations occurred in older patients, in patients not treated 
with pre-OP ~-blockers (t=21.8, p<0.001), in patients with abnormal post-OP electrocar- 
diograms (t=31.3, p<0.001), and especially in men (t=22.7, p<0.001 ). 
Conclusions: Minor elevations in cardiac troponin I levels in patients undergoing general 
surgical procedures strongly affect the post-OP outcome, especially during the first three 
months. 
1048-170 Cost of Abdominal Aortic Aneurysm Repair In Canada 
and the United States 
Anva C. Brox. Adk Azoulay, Kris Filion, Mark J. Eisenberg, Jewish General Hospital, 
Montreal, Quebec, Canada. 
Background: Many studies have compared health care costs in Canada and the United 
States (U.S.) on a macroeconomic level. However, little is known about the costs of spe- 
cific procedures. We therefore performed a microeconomic omparison of costs in 
abdominal aortic aneurysm (AAA) repair among Canadian and American patients. 
Methods: We compared the costs of treating 1,077 consecutive AAA repair patients 
(556 Canadian and 521 American) from 4 Canadian and 6 U.S. hospitals between 1997 
and 2001. All participating hospitals used the same cost accounting system to provide 
per-patient demographic, clinical, and cost data (excluding physician's fees), Canadian 
dollar costs were converted to U.S. dollar costs using purchasing power parities. 
Results: The mean age of AAA repair patients was similar in Canadian and American 
hospitals (69.9 ± 11.3 vs. 71.1 _+ 15.0years, p=ns) as was sex distribution (79.1% vs. 
76.0%, p=ns). The mortality rate in Canada was 12.1% vs, 10.0% (p=ns). Cost for AAA 
repair differed between Canadian and American hospitals. The median cost for AAA 
repair was $9,407 (mean $15,866 ± $18,631) in Canada as opposed to $13,802 (mean 
$24,582 ± $37,001) in the U.S. (p<0.0001). Direct costs accounted for 56.8% of total 
costs in the U.S. versus 67.1% in Canada. 
Conclusion: There is an approximate twofold difference in cost of AAA repair between 
the U.S. and Canada. Both direct and indirect costs are lower in Canada but direct costs 
make up a higher percentage of total cost than they de in the U.S. This cost discrepancy 
cannot be explained by differences in patient demographics or rates of in-hospital com- 
pUcations. 
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1073-163 Predictors of Hospital Outcome After First 
Percutaneous Coronary Intervention in the Community 
Audrey H. Wu, J. Richard Goss, Charles Maynard, Douglas K. Stewart, Xue-Qiao Zhao, 
University of Washington, Seattle. 
Background: Previous studies of hospital outcomes after first percutaneous coronary 
intervention (PCI) were performed prior to significant advances in PCI practice, or were 
performed in a retrospective or controlled manner. We examined the combined outcome 
of post-procedural myocardial infarction (MI) or in-hospital death after first PCI in a pro- 
spective manner, as currently practiced in the community. Methods: The Clinical Out- 
comes Assessment Program is a prospective, ongoing ststewide database that includes 
consecutive patients undergoing isolated PCI in Washington state (19 sites). Data from 
1/1/99 to 1/1/00 were obtained from COAP. Multivariate logistic regression modeling was 
used to determine risk of the combined outcome. Results: A total of 17,193 cases of first 
PCI were identified, including 11,399 (67.4%) males, with an average age of 63.9 + 12.2 
years. 3737 (21.9%) subjects had diabetes, 9946 (58.8%) had hypertension, and 2859 
(16.7%) had prior coronary bypass surgery. Significant predictors of the combined out- 
come include older age (20 year increments; adjusted OR 1.31; 95% CI 1.07, 1.60), 
shock (adjusted OR 2.73; 95% CI 1.70, 4.38), and more urgent priority vs. elective status 
(urgent - adjusted OR 1.74; 95% CI 1.18, 2.56; emergent - adjusted OR 5.95; 95% CI 
4.10, 8.65; salvage - adjusted OR 29.46; 95% CI 10.80, 80.31). PCI by slant vs. angio- 
plasty predicted lower incidence of the combined outcome (adjusted OR 0.69; 95% CI 
0.51, 0.93). Gender, history of diabetes, and treatment with glycoprotein (GP) Mb/llla 
inhibitors were not significantly associated with risk for the combined endpoint. Conclu- 
sion: Similar to previously published findings from retrospective series and clinical trials, 
several factors - including older age, shock, and more urgent priority - were associated 
with increased risk of post-procedural MI or in-hospital death among patients undergoing 
first PCI in the community. The lack of benefit seen with treatment with GP lib/Ilia inhibi- 
tors in the combined in-hospital endpoint may not necessarily contradict published find- 
ings, which primarily report improved intermediate-term Outcomes. 
1073-164 Predictors of Repeat Percutaneous Coronary 
Intervention Within One Year After First Percutaneous 
Coronary Intervention 
Audrey H. Wu. J. Richard Goss, Charles Maynard, Douglas K. Stewart, Xue-Qiao Zhao, 
University of Washington, Seattle. 
Background: Prior studies of repeat revasculadzation after first percutaneous coronary 
intervention (PCI) were performed in a retrospective or controlled manner, and were per- 
formed prior to recent advances in PCI practice. We determined the risk factors for 
revascularization by repeat PCI after first PCI in a prospective manner, as currently prac- 
ticed in the community. Methods: The Clinical Outcomes Assessment Program is a pro- 
spective, ongoing database that includes consecutive patients undergoing PCI in 
Washington state (19 sites). Data from 1/1/99 to 1/1/00 were analyzed. Repeat PCI was 
defined as a second PCI performed in the same coronary vessel territory 2-12 months 
after a first PCI. Multivariate logistic regression modeling was used to determine risk of 
repeat PCI. Results: 17,t93 cases of first PCI were identified, including 11,399 (67.4%) 
males, with an average age of 63.9 ± 12.2 years. 3737 (21.9%) subjects had diabetes 
and 2859 (16.7%) had prior coronary bypass surgery (CABG). 12,619 (82.6%) PCI pro- 
cedures were stents. Glycoprotein lib/Ilia inhibitors (GP2B3AI) were used in 11,569 
(67.9%) first PCI procedures. There were 924 cases of second PCI performed in any cor- 
onary vessel territory. Of these, 373 (40.4%) were repeat PCI. Prior CABG (adjusted OR 
1.59; 95% CI 1.18, 2.15) and chronic obstructive pulmonary disease (COPD) (adjusted 
OR 1.67; 95% CI 1.13, 2.48) significantly predicted repeat PCI. Lower incidence of 
repeat PCI was significantly associated with emergent vs. elective priodty (adjusted OR 
0.55; 95% CI 0.35, 0.88), use of GP2B3AI (adjusted OR 0.63; 95% CI 0.48, 0.81), and 
older age (20 year increments; adjusted OR 0.70; 95% CI 0.57, 0.86). History of diabetes 
was not significantly associated with risk of repeat PCI. Conclusion: in current commu- 
nity practice, treatment with GP2B3AI at the time of first PCI is one of the strongest pre- 
dictors of freedom from repeat PCI in the same coronary vessel distribution up to one 
year afterwards. Our data did not include repeat revascularization by CABG, which may 
explain why older age predicted a lower incidence, COPD predicted a higher incidence, 
and diabetes was not significantly associated with repeat PCI. 
1073-165 Low Body Mass Index Is an Important Correlate of Fatal 
and Nonfatal Complications After Percutaneous 
Coronary Interventions 
Maure Moscucci, Anthony C. DeFranco, David Share, Michael O'Dormell, William L. 
Meengs, Ann MaxwelI-Eward, John G. McGinnity, Kirit Patel, Vivian L. Clark, Dean E. 
Smith, Eva Kline-Rogers, Kim A. Eagle, For The Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium (BMC2), University of Michigan, Ann Arbor, Michigan. 
Body Mass index (BMI) has been found to be a risk factor for complications following cor- 
onary artery bypass surgery (CABG). There are currently no data on the relationship 
between BMI and complications following percutaneous coronary interventions (PCI). 
Thus, we evaluated the relationship between BMI and in-hospital outcomes of patients 
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undergoing PCI in a large regional multicenter database 
Methods. Clinical procedural and outcome data were prospectively collected between 
July 1997 and June 2001 from 19,142 PCI in a consortium of 8 hospitals in Michigan. 
BMI was divided in 5 categories; 1) <20 (underweight), 2) 20-25 (normal), 3) 25-30 (over- 
weight); 4) 30-40 (obese) and 5) >40 (morbidly obese). 
Result,=. Of 18,778 patients for whom complete weight and height data were available, 
2.1% were classified as underweight, 36% as obese and 5.2% as morbidly obese. 
Underweight patients were older and had a higher percentage of women when compared 
to the general population (p<0.05), while obese patients were younger. Underweight sta- 
tus was associated with a higher incidence of transfusion, contrast nephropethy, emer- 
gency CABG and in-hospital mortality (all p<0.05). After adjustment for comorbiditias, 
underweight status was an independent predictor of in-hospital death (p<0.05). 
Variable (%) BMI <20 BM120-25 BM125-30 BM130-40 BMI>40 
Age (years) 68.6±12.06 66.6±12.5 63.5±11.9 60.9±11.1 57.2±10.6 
Female sex 60 37.5 27.3 32.4 51.5 
Peripheral vascular disease 18.4 12.9 9.9 8.7 8.8 
Diabetes 18.4 16.8 22.0 33.6 50.4 
Creatinine >2 rag/d4 8.5 5.3 3.3 2.9 4.2 
Transfusion 11.0 6.6 4.4 3.4 4.0 
Vascular Complications 3.1 2.4 1.97 2.03 2.05 
Contrast nephropathy 2.8 1.6 1.0 0.9 1.2 
Emergency CABG 1.8 0.85 0.78 0.80 0.72 
In-Hospital death 4.1 2.2 1.5 1.13 1.5 
Conclusion. Patients with low BMI are at increased risk of fatal and non-fatal complica- 
tions following PCIs. 
1073-166 Pred ic tors  of  Length of Hospita l  Stay Af ter  
Contemporary  Coronary  Stent ing 
Mauro Moscucci, Dean E. Smith. David Share, Michael O'Donnell, Anthony C. 
DeFranco, Eva Kline-Rogers, Ann MaxwelI-Eward, John G. McGinnity, Kirit Patel, Vivian 
L. Clark, William L. Meengs, Diane Bondie, Kim A. Eagle, For The Blue Cross Blue 
Shield of Michigan Cardiovascular Consortium (BMC2), University of Michigan Health 
System, Ann Arbor, Michigan. 
Background: Post-procedure length of stay (LOS) is an important determinant of medi- 
cal costs following coronary stenting. Thus, identification of vadablas related to LOS may 
be important for quality improvement and cost reduction efforts. 
Methods: We evaluated 19,142 patients who underwent contemporary coronary stenting 
in a consortium of 8 hospitals. Predictors of log-transformed LOS were identified using 
multiple linear regression (MLR) modeling. Variables evaluated in sequence included 
pre-, intra- and post-procedure factors, and adverse outcomes. 
Resulta: In this large dataset, pre-procadure factors alone explained 20% of variability in 
post-procedure LOS (adjusted r square=0.197). The addition of procedural variables 
added little to the model (adjusted r square=0.22), while in the final model, addition of 
outcome variables further increased the overall predictive capacity (adjusted r 
squara=0.29). Female gender, advanced age, CHF, acute MI, cardiogenic shock, diabe- 
tes, emergent or urgent procedure, dialysis dependent renal failure, history of cardiac 
arrest, low ejection fraction and valvular heart disease were baseline independent clinical 
correlates of LOS (all p<O.05), while administration of pre and post procedure hepadn, of 
post procedure low molecular weight hepadn, use of Glycopretein itb/llla receptor block- 
ers, and use of intraaortic balloon pumps were care-process variables related to longer 
LOS (all p < 0.001). Vascular complication, unplanned CABG, blood transfusion, repeat 
procedures, contrast nephropathy, arrhythmias, post procedure stroke and MI were addi- 
tional outcome variables associated with increased LOS (all p_<0.01). 
Conclusion: 1) Baseline clinical characteristics are important correlates of LOS follow- 
ing coronary stenting 2) The identification of process of care variables and complications 
associated with increased LOS highlights important targets for quality improvement and 
cost reduction efforts. 
1073-167 Effect of Tlrofiban Versus Abciximab on Six-Month 
Hospi ta l i zat ion Rates for Acute Cardiac Events Among 
Pat ients  Undergo ing  Percuteneoua Coronary  
Intervent ion  
Glenn M. Davies. John R. Cook, Peter M. DiBattiste, Laura Demopoulos, for the 
TARGET investigators, Merck Research Laboratories, Blue Be//, Pennsylvania. 
Background: In the TARGET Study, patients received either tirofiban or abciximab dur- 
ing percutaneous coronary revascularization with the intent to perform stent. At 30 days, 
there were fewer major ischemic events among patients who received abciximab, but the 
treatment difference diminished and was not significant at 6 months. We assessed 
whether there were treatment differences in the 6-month hospitalization rate and total 
bed days for major ischemic events. 
Methods: Admission and discharge dates and data on repeat procedures (PCI and 
CABG) were collected for the initial hospitalization and for each subsequent hospitaliza- 
tion for an acute ischemic event (MI or repeat PCI or CABG) that occurred within 6 
months of randomization. The average remaining length of stay for the initial hospitaliza- 
tion following randomization, the number of hospitalizations for acute ischemic events, 
the total number of bed clays and the number of repeat procedures were estimated for 
the two treatments. Treatment differences and 95% bootstrap confidence intervals were 
obtained. 
Results: Results are shown in the table below. No significant differences were found. 
ABSTRACTS - Special Topics 439A 
Abciximab Tirofiban Difference (95% CI) 
(n=2411) (n=2398) 
Initial Hospitalizatiofl 
Repeat PCI/CABG (per 100 pts) 0.79 0.75 -0.04 ( -0.54; 0.42) 
Average Length of Stay (days) 1.57 1.60 0.03 ( -0.08; 0.15) 
6 Month (Post-Discharge) 
Hospitalizations (per 100 pts) 9.42 8.92 -0.50 ( -2.24; 1.21) 
Repeat PCI/CABG (per t 00 pts) 8.63 8.13 -0.49 ( -2.40; t .33) 
Total Bed Days (per t00 pts) 34.91 38.11 3.20 ( -7.61; 13.89) 
Conclusion: At 6 months, there were no significant differences in the rates of hospital- 
izations or total bed days for acute cardiac events. A 6-month cost analysis that includes 
both study medication and hospitalizations for acute cardiac events is planned. 
1073-168 International Differences in Cost, Medical Resource 
Utilization, and Clinical Event Rates in a Large 
Percutaneous Coronary  In tervent ion  Study:  Resul ts  
From the  EXCITE Trial 
Conor O'Shaa. Joelle Y. Friedman, Karen Pieper, Kasem S. Akhras, Kevin A. Schulman, 
Duke Clinical Research/nstitute, Durham, North Carolina. 
Background: The extent to which international differences in the intensity of medical 
practice impact on patient outcomes is an important issue. We examined the medical 
costs and cardiovascular outcomes of 7232 patients undergoing coronary intervention at 
412 centers including North and South America and Europe in the EXCITE trial. 
Methods: Resources required to treat major cardiovascular events were recorded in the 
case report forms. Resource use data collected included information about hospital stay, 
and specific cardiovascular procedures. Costs for these resources were assessed at an 
individual patient level. Cost estimates for specific rasourcas were collected from cost 
analysts in each country. Unit cost estimates were converted to U.S. dollars using OECD 
Purchasing Power Parity (PPP) conversion rates. US costs were estimated by applying 
national average DRG reimbursements to hospitalizations and assigning costs to individ- 
ual CPT codes for both outpatient and inpatient procedures. 
Results: Costs were greatest in the US. In several countries, the 6 month composite of 
death and MI was significantly less than in the US, although these data have not been 
adjusted for differences in baseline risk. 
Conclusions: Even within the confines of a muiticanter clinical trial, there are significant 
international differences in resource utilization, medical costs and clinical event rates. 
These regional differences are likely to have important implications for trial design and 
sample-size calculations. 
Country (n) Cost ($) [Median (25, 75)] Death/MI at 6 Months 
Chile(61) 3459 (2189, 4626) 3.3% 
Mexico (142) 4030 (3279, 6760) 7.6% 
United Kingdom (222) 7608 (5683,11960) 4.0% 
Germany (350) 7760 (5988, 11866) 2.3% 
France (291) 9259 (8725, 17224) 3.8% 
United States (2871) 12779 (9681, 22460) 6.6% 
1073-169 Practice and Outcome Variations in Percuteneous 
Coronary Intervention: An Ana lys i s  o f  a Large 
Mult icenter  PCI Database 
Mauro Moscucci, Dean E. Smith, David Share, Michael O'Donnell, Anthony C. 
DeFranco, William L. Masngs, Ann MaxwelI-Eward, John G. McGinnity, Kirit Patel, Vivian 
L. Clark, Eva Kilns-Rogers, Diane Bondie, Kim A. Eagle, For The Blue Cross Blue Shield 
of Michigan Cardiovascular Consortium (BMC2), University of Michigan, Ann Arbor, 
Michigan. 
The objective of our study was to evaluate practice and outcome variation with contem- 
porary percutaneous coronary interventions (PCI) as potential targets for quality 
improvement. 
Methods. Clinical, procedural and outcome data were prospectively collected between 
July 1997 and June 2001 from 19,142 PCI in a consortium of 8 hospitals in Michigan. 
Practice and outcome variation among the 8 hospitals were evaluated by calendar year 
(1998, 1999 and 2000). 
Results. Variation in resource utilization and outcomes are listed in the table. Data are 
expressed as percentage unless otherwise indicated. Numbers indicate average for the 
collaborative group, and lowest and highest frequencies. 
Variable Year 1998 Year 1999 
Pre procedure aspirin 
Use of Non Ionic Contrast 
Amount of Contrast/case 
(cc) 
Gp lib/Ilia receptor blocker 
use 







Low, Average,High Low,Average,High Low,Average,High 
89.4 - 92.4 - 97.2 87.5 - 94.3 - 98.8 75.3 - 90.5 - 98.3 
17.7 - 68 - 100 29.6 - 78.9 - 100 37.9 - 84.8 - 99.8 
202 - 248 - 334 178 - 232 - 295 t 64 - 222 - 295 
13.4 - 31.3 - 48.4 32.3 - 43.6 - 82.1 49.6 - 61.7 - 91.8 
17.5 - 34.9 - 76.3 11.3 - 38.3 - 61.9 6.6 - 24.6 - 77.7 
0.34 - 0.9 - 2.44 0.11 - 0.52 - 1.55 0.22 - 0.72 - 1.8 
3.3 - 4.2 - 9.1 2.24- 4.46 - 6.8 2.24 - 4.7 - 8.61 
1.36 - 2.14 - 3.15 0.92 - 1.93 - 3.61 0.84 - 1.93 - 3.89 
0.30 - 1.0 - 1.67 0.16 - 0.64 - 1.44 0.22 - 0.7 - 1.3 
0.74 - 1.68 - 2.33 0.76 - 1.36 - 2.51 0.5 - 1.5 - 2.4 
Conclusion. 1 ) Substantial practice and outcome variation exists with contemporary PCI 
practice. 2) Analysis of this variation identifies potential targets for quality improvement 
programs in PCIs. 
